Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Phase III Multicenter, Randomized, Blinded, Placebo-controlled Trial Assessing the Efficacy, Safety, and Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Adults Aged ≥60 Years

Authors not listed

Beijing BeneWill Technology Development Co., Ltd · 2026

Abstract

This is a phase III clinical trial with a multicenter, randomized, blinded, placebo-controlled design to evaluate the protective efficacy, safety, and immunogenicity of the recombinant respiratory syncytial virus (RSV) vaccine (CHO cell) in individuals aged 60 and above. Sample Size and Trial Grouping: This trial plans to enroll 25,000 trial participants aged ≥60 years (with approximately 30% aged 70 and above), with a relatively balanced gender distribution. Participants of each age group (60-69 years old, ≥70 years old) will be randomly assigned to the trial group and the placebo group in a 1:1 ratio. The sample size for the immunogenicity subgroup is not calculated based on statistical power. Referring to similar clinical trials of RSV vaccines and in conjunction with the immunogenicity observation objectives of this trial, the first 300 trial participants (including those from both age groups) from each site under the leading institution will be included in the immunogenicity subgroup, for a total of 1,200 participants.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-10 MST

Cite this

APA
Anonymous. (2026). Phase III Multicenter, Randomized, Blinded, Placebo-controlled Trial Assessing the Efficacy, Safety, and Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Adults Aged ≥60 Years. <em>Beijing BeneWill Technology Development Co., Ltd</em>. https://clinicaltrials.gov/study/NCT07860216
Vancouver
Anonymous. Phase III Multicenter, Randomized, Blinded, Placebo-controlled Trial Assessing the Efficacy, Safety, and Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Adults Aged ≥60 Years. Beijing BeneWill Technology Development Co., Ltd. 2026.
BibTeX
@misc{anon2026PhaseI, title = {Phase III Multicenter, Randomized, Blinded, Placebo-controlled Trial Assessing the Efficacy, Safety, and Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Adults Aged ≥60 Years}, author = {Anonymous}, journal = {Beijing BeneWill Technology Development Co., Ltd}, year = {2026}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings